Indication
Hemoglobin H disease
Hemoglobin H disease is a moderate-to-severe form of alpha-thalassemia, a genetic hematologic disorder caused by the loss or inactivation of three of the four functional alpha-globin genes. Read more about Hemoglobin H disease
1 drugs 1 manufacturers
Drugs that treat it
Common Hemoglobin H disease therapies.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonHemoglobin H disease is a moderate-to-severe form of alpha-thalassemia, a genetic hematologic disorder caused by the loss or inactivation of three of the four functional alpha-globin genes.
This deficiency produces an imbalance between alpha- and beta-globin chains, resulting in the assembly of unstable beta-globin tetramers known as hemoglobin H within erythrocytes.
The condition primarily impacts the hematologic and reticuloendothelial systems, leading to chronic microcytic hypochromic hemolytic anemia, ineffective erythropoiesis, splenomegaly, and jaundice.
Clinical manifestations range from mild thalassemia intermedia to severe anemia with complications such as cholelithiasis, acute hemolytic crises triggered by infections or oxidant stress, and secondary iron overload.
- nih.gov
Hemoglobin H disease is a moderate-to-severe form of alpha-thalassemia, a genetic hematologic disorder caused by the loss or inactivation of three of the four functional alpha-globin genes The condition primarily impacts the hematologic and reticuloendothelial systems, leading to chronic microcytic hypochromic hemolytic anemia, ineffective erythropoiesis, splenomegaly, and jaundice Clinical manifestations range from mild thalassemia intermedia to severe anemia with complications such as cholelit...
- nih.gov
Hemoglobin H disease is a moderate-to-severe form of alpha-thalassemia, a genetic hematologic disorder caused by the loss or inactivation of three of the four functional alpha-globin genes The condition primarily impacts the hematologic and reticuloendothelial systems, leading to chronic microcytic hypochromic hemolytic anemia, ineffective erythropoiesis, splenomegaly, and jaundice Clinical manifestations range from mild thalassemia intermedia to severe anemia with complications such as cholelit...
- ucsf.edu
This deficiency produces an imbalance between alpha- and beta-globin chains, resulting in the assembly of unstable beta-globin tetramers known as hemoglobin H within erythrocytes
- nih.gov
This deficiency produces an imbalance between alpha- and beta-globin chains, resulting in the assembly of unstable beta-globin tetramers known as hemoglobin H within erythrocytes The condition primarily impacts the hematologic and reticuloendothelial systems, leading to chronic microcytic hypochromic hemolytic anemia, ineffective erythropoiesis, splenomegaly, and jaundice
Personalize your experience
Follow Hemoglobin H disease and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.